Roth/MKM Starts CervoMed (CRVO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St set for higher open as Anthropic's IPO filing sharpens AI focus
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
- Serbia's Vucic concedes defeat to student led movement in parliamentary election
H.C. Wainwright Starts CervoMed (CRVO) at Buy
December 5, 2024 6:05 AM ESTH.C. Wainwright analyst Raghuram Selvaraju initiates coverage on CervoMed (NASDAQ: CRVO) with a Buy rating and a price target of $42.00.
For an analyst ratings summary and ratings history on CervoMed click here. For more ratings news on CervoMed click here.
Shares of CervoMed closed at $9.70 yesterday.
... More


